research reports and media, page-1598

We should know before 1st week of August.
before..
EOM May for questions
EOM June - latest to respond.
EOM July -FDA response
PAR update the market -- .
tea leave Price 3.22
IMO. DYOR.

By the way, i read back to a 2018/9 Frost evaluation which priced a Phase 2 outcome at 90% to be worth $5.22.
So here we are entering phase 3.

Why the gap in the current price v predicted?

I think value investing is back in play, with a twist.
Afterpay and ZIP have dropped significantly since February and they have growing revenue.

What is the general state of the market...
(1) It is cheap to leverage purchases, but with leveraging comes risk.
(2) Asset prices/Income are very high because interest rates are very low.
What sort of assets will be bought - those with relatively low risk.
(3) Risk is higher the further out you have to wait

Put those together and you can see active investors prefer returns from current net profit > OCF positive >revenue growing > > future potential
--- and Instos and ETFs following those trends.

The pre 2021 guideline of 7x revenue for bio and tech stocks is now over-optimistic. So there is a re-weighting of risk going on. Not helped by any non-positive news,

Frost just put out another stock analysis. What is interesting about it is how they come up with the price and how that analysis relates to PAR given the lead-times.

https://mcusercontent.com/1c0f579e5b363ed254cfdb86a/files/13940598-4a87-cb28-2970-d2cc35d1bdfa/Frost_Sullivan_Weebit_Update_Report_120521.pdf

In the context of how i see the market, the price fall to $2.04 is mainly due to
(1) the FDA etc delays from when $2.50 or so
(2) altered view by the market on time delay to significant revenue,
(a) below 5 without the pandemic effect on risk
(b) below 3 post pandemic


GLTAH.
DYOR.